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Plasma concentrations of proinsulin are raised in sub-
jects with Type II (non-insulin-dependent) diabetes
mellitus [1]. Proinsulin is normally converted within
the beta-cell into split proinsulin and subsequently
into insulin and C-peptide [2]. In subjects with im-
paired glucose tolerance (IGT), the relative (to insu-
lin) proinsulin and absolute proinsulin concentrations
are important predictors of progression to Type II di-
abetes [3, 4]. These findings are often interpreted as
early indicators of an impaired beta-cell function but
the mechanisms underlying the increase in proinsulin
have still not been established. The results of some
studies among patients with Type II diabetes have
suggested that an inherent beta-cell defect is respon-
sible for raised proinsulin [5, 6], whereas studies with
rats [7] and hemipancreatectomised patients [8] have
suggested that an increased secretory demand on the
beta-cells is responsible. In Type II diabetes, hyper-
glycaemia per se could contribute to the beta-cell de-
fect. Therefore, studies on subjects with IGT, in
which the adverse effects of hyperglycaemia are sup-
posed to be limited, might provide a better insight
into the initial underlying cause(s) of (relatively) in-
creased proinsulin concentrations. In this study, 110
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Summary In subjects with impaired glucose toler-
ance hyperproinsulinaemia has been shown to be pre-
dictive for progression to Type II (non-insulin-depen-
dent) diabetes mellitus. These findings are often in-
terpreted as early indicators of an impaired beta-cell
function. The aim of our study was to assess the po-
tential determinants of hyperproinsulinaemia in sub-
jects with impaired glucose tolerance. The study
group consisted of 110 subjects, 45±74 years of age
with mean 2 h plasma glucose concentrations be-
tween 8.6 and 11.1 mmol/l following two oral glucose
tolerance tests. Subsequently, the hyperglycaemic
clamp technique (10 mmol/l, with a priming infusion
of 20 % glucose solution, 150 mg/kg) was used to as-
sess the beta-cell function (time needed to reach the
insulin peak) and insulin sensitivity (M/I value: glu-
cose metabolised divided by insulin response,
150±180 min). Results showed that the intact-proin-
sulin:insulin ratio increased with increasing time
needed to reach the insulin peak (0.065, 0.079 and
0.101; time needed to reach the insulin peak £ 5 min,
5 to 15 min, > 15 min; p < 0.05). The split-proinsu-
lin:insulin ratio showed a similar association with the
time needed to reach the insulin peak. These associa-
tions were independent of age, sex, body mass index
and waist:hip ratio. In conclusion, this study shows
that relative hyperproinsulinaemia is associated with
an impaired beta-cell function in a study group of
subjects with impaired glucose tolerance selected af-
ter two oral glucose tolerance tests. [Diabetologia
(1999) 42: 177±180]
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subjects with IGT were selected, and potential deter-
minants of (relative) proinsulin concentrations, such
as beta-cell function, insulin sensitivity, glucose con-
centration and obesity indices were studied.
Materials and methods
Subjects. Participants were selected from a random sample of
45±74 year-old subjects, taken from the population register of
the town of Hoorn in The Netherlands. Of the subjects who re-
ceived a postal invitation to undergo a blood glucose test
(n = 12 093), 55 % visited the study centre. Subjects with a fast-
ing plasma glucose more than 5.5 mmol/l (n = 3147) underwent
a complete oral glucose tolerance test (OGTT), which was re-
peated on another day if the 2-h plasma glucose value exceed-
ed 7.8 mmol/l (n = 554). Subjects with a mean 2-h plasma glu-
cose concentration between 8.6 and 11.1 mmol/l after two OG-
TTs were invited to participate in the study. This narrow range
within the impaired glucose tolerance criterion according to
the World Health Organisation (WHO) [9] was chosen to en-
sure that the participants were definitely at high risk of devel-
oping diabetes [4]. Written informed consent was obtained
from the participants after the protocol had been approved by
the medical ethics committee of the Academic Hospital of the
Vrije Universiteit.
Hyperglycaemic clamp study. All 110 participants in the study
underwent a hyperglycaemic clamp test [10], in the fasting
state and in a supine position, which commenced between
0800 and 0830 hours. Insulin and glucose were measured in ve-
nous blood, after arterialization was obtained by placing the
hand of the subject in a thermo-regulated box at 45 °C.
Baseline samples were drawn for glucose and insulin mea-
surements, 30 and 15 min before the beginning of the clamp.
The clamp started with a priming infusion of a 20 % glucose so-
lution, 150 mg/kg, which was given to rapidly raise the blood
glucose concentration to approximately 10 mmol/l. The blood
glucose concentration was subsequently measured at 5-min in-
tervals and a variable glucose infusion was adjusted to main-
tain the plasma glucose concentration at 10 mmol/l for 3 h.
Blood samples for insulin measurements were obtained at
2.5 min intervals for the first 10-min, 5-min intervals for the
second 10-min and at 10-min intervals for the remaining period
of 160 min. Under these stable conditions of constant hyper-
glycaemia, the amount of glucose infused (mg × kg±1 × min±1)
gives an estimate of the glucose that is metabolised (M). The
amount of M divided by the plasma insulin response (insulin
in pmol/l) provides an estimate of the tissue sensitivity (mg ×
kg±1 × min±1 per pmol × l±1) to endogenously secreted insulin in
healthy subjects [10], and in subjects with impaired glucose tol-
erance (unpublished observations). As a variable of beta-cell
function an estimate was made of the time needed to reach
the insulin peak. The insulin peak was defined as the first high-
est insulin value after initiation of the clamp, which was fol-
lowed by an insulin value lower than the `critical difference'
between the two values. The `critical difference', at a 0.05 level
of significance, was defined as 1.96 times 2 times the coefficient
of variation for the total within-subject variation [11]. The time
needed to reach the insulin peak was used as a variable of the
beta-cell function. The first phase insulin response
(pmol × l±1 × min±1), the standard variable of the beta-cell func-
tion [10], was not used, since the insulin response during the
first 10 min of the clamp was partly absent in this particular
study group (Fig. 1).
Biometry and laboratory analyses. Height, weight, and waist
and hip circumference were measured according to standard
procedures and used to calculate body mass index (kg/m2) and
waist:hip ratio [12]. Venous whole-blood glucose (mmol/l) was
determined by a YSI glucose analyser (YSI, Yellow Springs,
Ohio, USA). Specific insulin, intact and total proinsulin were
measured in fasting plasma samples drawn before the OGTT
(e. g. unheated hand). Insulin was measured by a two-site im-
munoradiometric assay, using a pair of monoclonal antibodies
(Medgenix Diagnostics, Fleurus, Belgium). This assay does
not cross-react with proinsulin and 32±33 split proinsulin. The
lower limit of detection was 10 pmol/l. The intra-assay coeffi-
cient of variation (CV), as determined by replicate analysis of
samples, was less than 5 %; the interassay CV was less than
10 % over the concentration range 40±1200 pmol/l. Intact pro-
insulin was measured by a two-site enzyme immunoassay
(K6242, DAKO, Ely, Cambridgeshire, UK), using a pair of
monoclonal antibodies. The capture antibody A6 binds to the
B-C junction of proinsulin. The detector antibody (3B1) recog-
nises the B10-B16 epitope on the B-chain of proinsulin. This
combination of antibodies enables the detection of intact pro-
insulin along with des 64±65 and 65±66 split proinsulin. These
intermediate forms of proinsulin are not normally produced in
appreciable quantities, therefore the assay effectively measures
only intact proinsulin. The antibodies and a prototype of the as-
say have been described previously [13]. The assay is calibrated
against the first WHO International Reference Reagent (IRR)
of proinsulin. The lower limit of detection was 0.5 pmol/l. The
intra-assay CV, as determined by replicate analysis of samples
over the range 0±90 pmol/l, was less than 4 %. The interassay
CV was less than 8 % over the concentration range 4±30 pmol/l.
Total proinsulin was measured by a two-site enzyme immu-
noassay (K6243, DAKO, Ely, Cambridgeshire, UK), using a
pair of monoclonal antibodies. The capture antibody (3B1)
binds to the B10-B16 epitope on the B-chain of proinsulin.
The detector antibody (PEP001) binds somewhere in the C-ter-
minal portion of the proinsulin molecule. This pair of antibod-
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Fig. 1. Insulin response to glucose in subjects with impaired
glucose tolerance and a varying beta-cell function. The beta-
cell function is expresssed as the time needed to reach the insu-
lin peak: U, £ 5 min; k, > 5 min and £ 15 min; D, > 15 min (see
text)
ies detects all intermediate forms of proinsulin in addition to
the parent molecule. The configuration (3B1 a capture anti-
body) gives no clinically relevant cross-reaction with either in-
sulin or C-peptide. The antibodies and prototypes of the assay
have been described previously [13, 14]. The assay is calibrated
against the first WHO IRR of proinsulin. The lower limit of de-
tection was 0.5 pmol/l. The intra-assay CV, as determined by
replicate analysis of samples over the concentration range of
0±90 pmol/l, was less than 5 %. The interassay CV was less
than 7 % over the concentration range 8±50 pmol/l. The con-
centration of split proinsulin (pmol/l) was calculated by sub-
tracting the measured intact proinsulin of the measured total
proinsulin. This calculated split proinsulin approximately rep-
resents the concentration of 32±33 split proinsulin.
Statistical analysis. Data are presented as medians (33rd and
67th percentile). To show the magnitude of associations be-
tween (relative) (pro) insulin concentrations and potential de-
terminants, analysis of covariance and linear regression analy-
sis was applied. Analysis of covariance provides insight into
non-linear associations, whereas linear regression analysis pro-
vides insight into linear associations. Both methods enable ad-
justment for the influence of potential confounders. Distribu-
tions of the intact and split proinsulin and their ratios were nor-
malised by transformation into their natural logarithm to im-
prove the plots of residual analyses. Results were expressed
as geometric means, adjusted for age and sex (analysis of cova-
riance), and as percentage differences in (relative) (pro) insu-
lin (and their 95 % confidence intervals) associated with a
change of the 33rd to the 67th percentile of the determinant
of interest. A zero within the 95 % confidence interval implies
that no independent statistically significant (p < 0.05) associa-
tion was observed. One subject was regarded as an exception
and therefore excluded from the analysis, since the first phase
insulin response was twice the value of the second in line. Ex-
clusion of this subject did not substantially affect the results.
Analyses were made with the SPSS-PC software package
(SPSS, Chicago, Ill., USA).
Results
The clinical and biochemical characteristics of the
impaired glucose tolerant study group are shown in
Table 1. The median age was 57 years and 50% were
women. The study group was characterised by, either
an impaired beta-cell function, insulin resistance, or
a combination of both defects. Figure 1 depicts the
beta-cell function of the study group by the insulin re-
sponse to the standardised hyperglycaemic stimulus.
In these subjects, the intact and split-proinsulin:in-
sulin ratios were associated with the beta-cell func-
tion. The intact-proinsulin:insulin ratio increased
with increasing time needed to reach the insulin peak
(0.065, 0.079 and 0.101; time needed to reach the insu-
lin peak £ 5 min, 5 to 15 min, > 15 min; p < 0.05). The
split-proinsulin:insulin ratio showed a similar associa-
tion with the time needed to reach the insulin peak
(Table 2). These associations were independent of
age and sex. Multiple linear regression analyses con-
firmed these associations and showed that they were
also independent of obesity indices (Table 2). The per-
centage difference (and 95% CI) in intact and split-
proinsulin:insulin ratio associated with the beta-cell
function (a difference of 10 min in time needed to
reach the insulin peak) was 5%(1 to 9 %) and 5%
(0 to 9 %), respectively. Repeating these analyses, in-
cluding insulin sensitivity, fasting plasma glucose, 2 h
plasma glucose, HbA1 c, variables of the liver or kid-
ney function as possible confounders into the regres-
sion model, the percentage difference in relative hy-
perproinsulinaemia associated with the beta-cell func-
tion did not shift substantially (data not shown). Thus,
the intact and split-proinsulin:insulin ratios were inde-
pendently associated with a delayed insulin response
of the beta-cells to a standardised glucose stimulus.
Discussion
Our study shows that relative hyperproinsulinaemia
is associated with a delayed insulin response to glu-
cose in a homogeneous impaired glucose tolerant
study group. The study subjects were at a high risk
of developing Type II diabetes, since they were se-
lected on the basis of a mean 2-h plasma glucose con-
centration between 8.6 and 11.1 mmol/l [4].
The results of some studies suggest that, either an
inherent beta-cell defect [5, 6] or an increased secre-
tory demand [7, 8] is responsible for relative hyper-
proinsulinaemia. The results of our study suggest
that an impaired beta-cell function is primaryly re-
sponsible for relative hyperproinsulinaemia. Results
of an earlier study in the same group showed that an
impaired beta-cell function was associated with an in-
creased secretory demand for insulin, represented by
a higher concentration of fasting plasma glucose
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Table 1. Characteristics of the study group with impaired glu-
cose tolerance
Mean 2 h-plasma glucose concentration
between
8.6 and 11.1 mmol/l
Sex (M = men, W = women) 54 M; 55 W
Age (years) 57.0 (52.6±62.0)
Fasting plasma glucose (mmol/l) 6.6 (6.3±6.9)
HbA1c (%) 5.7 (5.4±5.9)
Body mass index (kg/m2) 27.2 (26.3±29.5)
Waist-to-hip ratio 0.92 (0.90±0.96)
beta-cell functiona (min) 8 (5±15)
Insulin sensitivity (100  mg × kg 1 ×
min 1 per pmol × l 1) 1.44 (1.01±1.75)
Fasting specific insulin (pmol/l) 69.9 (60.3±88.0)
Fasting intact proinsulin (pmol/l) 5.22 (4.40±7.30)
Fasting split proinsulin (pmol/l) 9.70 (8.00±14.98)
Intact-proinsulin : insulin ratio 0.075 (0.062±0.096)
Split-proinsulin : insulin ratio 0.160 (0.115±0.201)
Values are medians (33 rd and 67 th percentile) unless other-
wise indicated.
a The time needed to reach the insulin peak (see text)
[15]. In this study, no association was found between
relative hyperproinsulinaemia and insulin sensitivity,
in contrast to another study [16] in which a negative
association was found in 138 people with normal glu-
cose tolerance. The discrepancy between the two
studies might be explained by glucose tolerance sta-
tus or by a small difference in statistical power.
Our results show further that the relative intact
and split proinsulinaemia increased in proportion to
an impaired beta-cell function, which suggests that
the orderly cleavage of proinsulin is maintained. Ex-
haustion of the beta-cells also seems likely because
an association between the proinsulin:insulin ratio
and the beta-cell function in hemipancreatectomised
patients has been found [8]. An inherent abnormality
of the conversion process of proinsulin to insulin [2]
cannot, however, be excluded by our study and might
be investigated by more detailed experimental stud-
ies on the role of intracellular Ca2+ metabolism and
related signalling pathways for the processing and
transport of proinsulin [17]. External factors related
to obesity might also affect the proinsulin conversion
mechanism, which was suggested by the confounding
influence of obesity indices and by a recent study on
non-esterified fatty acids [18]. In conclusion, relative
hyperproinsulinaemia is associated with the beta-cell
function, reflected by a delayed insulin response to a
standardised hyperglycaemic stimulus.
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Table 2. Associations between (relative) (pro) insulin concentrations and beta-cell function in subjects with impaired glucose toler-
ance
(Relative) (pro) insulin
Beta-cell function, expressed as the time needed
to reach the insulin peak
Percentage difference in (relative) (pro) insulin
associated with a change of 10 min of the time
needed to reach the insulin peakb
K 5 min > 5 and K 15 min > 15 min % difference and 95% confidence interval
Specific insulin (pmol/l) 74.5 73.4 65.4 2 5 to 1
Intact proinsulin (pmol/l) 4.80 5.74 6.88 3 1 to 7
Split proinsulin (pmol/l) 10.05 11.08 13.79 3 2 to 8
Intact-proinsulin : insulin ratio 0.065 0.079 0.101a 5 1 to 9
Split-proinsulin : insulin ratio 0.137 0.154 0.203a 5 0 to 9
Left hand: values are geometric means adjusted for age and
sex, a p -value < 0.05 (analysis of covariance)
b Right hand: associations are adjusted for age, sex, body mass
index and waist-to-hip ratio and calculated with the help of lin-
ear regression models (see text)
